Aimovig Approved to Prevent Migraines
Aimovig is the first FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of calcitonin gene-related peptide, a molecule involved in migraine attacks, the agency said in a news release.
"We need new treatments for this painful and often debilitating condition," said Dr. Eric Bastings, deputy director of the FDA's Division of Neurology Products.
Migraines are typically characterized by intense pulsing or throbbing pain on one side of the head. The headache may be accompanied by nausea, vomiting and sensitivity to light and sound. About a third of sufferers have the migraine preceded by an aura, which is described as flashing lights, zig-zag lines or temporary vision loss.
People who have migraines tend to have repeated attacks, which can be triggered by factors including stress, hormonal changes, diet, or lack of food or sleep, the FDA said.
Aimovig was evaluated in clinical studies involving more than 2,000 people. The drug's most common side effects included injection-site reactions and constipation.
Aimovig is produced by Amgen Inc., based in Thousand Oaks, Calif.
© 2020 HealthDay. All rights reserved.
Posted: May 2018
Read this next
MONDAY, Sept. 28, 2020 -- Could migraine risk be affected by sexual orientation? A new study suggests that the answer may be yes. After tracking migraines among thousands of...
MONDAY, Sept. 21, 2020 -- Many women with severe migraines don't want to get pregnant because of concerns about their headaches, a new study finds. Migraine, one of the world's...
THURSDAY, May 21, 2020 -- Boosting doses of opioid pain medicines doesn't appear to benefit patients with chronic pain, researchers report. "What we found was that the pain...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.